miR-128 has been found to block the p38 MAPK pathway, which inhibits the production and production of IL-6 and IL-10 while increasing the amount of IL-12 in DCs., hence boosting the anti-cancer immunity of DCs and decreasing cancer progression in melanoma (22). Here, IL6 is linked to melanoma.